“…PTMs on biotherapeutic proteins are monitored as potential CQAs to inform process development, batch consistency, product stability, and more, as their presence can influence product quality, efficacy, and potentially patient safety. ,− Comprehensive PTM analysis is crucial for in-depth characterization of full-length AAV VPs, as it aids in the proper identification of different VP proteoforms present and any potential consequences their presence might cause. For PTM determination, peptide mapping and relative PTM quantitation of AAV2 using on-bead pepsin digestion and nano-LC separation were performed in parallel to full-length VP analysis, following the procedure described by Guapo et al One hundred percent sequence coverage was obtained after filtering identified peptides in BPF as described in the section describing AAV peptide mapping data processing for improved peptide mapping confidence (Figure S1). Here, it should be noted the VP1 sequence searched for peptide mapping was A2-735 as it is well-known that for AAV2 the N-terminal methionine (M, Met) residue is cleaved within the cell ,,, (Figure ).…”